GUJTHEM · Health Care · 2026-08-21

Gujarat Themis Biosyn Ltd

Stage 3 · wk 3In scan: Prop Scan · Breakout WatchMARKET: BULL RISING · 2026-08-21
₹381.2
+3.24% today
₹4,161 Cr · Small cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O for the treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.

Visit company website →
P/E (TTM)
98.7
Forward —
Earnings Growth (YoY)
-9.1%
Revenue +19.7%
ROE
+17.4%
Profit margin +27.7%
Dividend Yield
0.18%
P/B 17.8
vs 52W High
-18.9%
₹226.9 lo₹469.9 hi
18.9% below 52W high — weakening from peak
Stock is rolling over from its 52W high. Stage 3 distribution — new longs are high risk here.
Stage Maturity
Week 3
1w13w26w
Week 3 — early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
4.7%
200 DMA: ₹364 · sloping down
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
1.65x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution — institutions are exiting. A clear warning to avoid new longs.
Trend Health
↓
MA20 rolling over · -0.5% vs MA50 -2.7%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
Sector has 84 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↑ Building
Stage 2%
56.1%
20d Δ
+5.6pp
1M return
+2.7%
3M return
+10.4%
Industry Stage-2 % · last 20 days
Industry has 58 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2025-02-25 → 2026-08-21
S? 42w
S3 8w
S4 11w
S1 7w
2025-02-252026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 42w → S2 1w → S3 8w → S4 11w → S1 7w → S2 6w → S3 3w current
Total tracked: 77 weeks across 7 stage runs.
1M
+7.0%
3M
+3.4%
6M
+20.5%
YTD
-14.0%
1Y
+6.9%
Scan Membership
Prop Scan
Latest: 2026-07-06
Breakout Watch
Latest: 2026-06-25
9 appearances in last 60 days. First seen: 2025-12-17.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S3
Wk 3 · Vol —x
2026-08-20S3
Wk 3 · Vol —x
2026-08-19S3
Wk 3 · Vol —x
2026-08-18S3
Wk 3 · Vol —x
2026-08-17S3
Wk 2 · Vol —x
2026-08-14S3
Wk 2 · Vol —x
2026-08-13S3
Wk 2 · Vol —x
2026-08-12S3
Wk 2 · Vol —x
2026-08-11S3
Wk 2 · Vol —x
2026-08-10S3
Wk 1 · Vol —x
2026-08-07S3
Wk 1 · Vol —x
2026-08-06S3
Wk 1 · Vol —x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹371.6
200 DMA
₹364
52W High
₹469.9
52W Low
₹226.9
5D Low
₹351.3
Resistance levels (recent highs)
20d High
₹381.2
60d High
₹413.2
120d High
₹432.2
250d High
₹469.9
Next resistance
+8.4%
to 60d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.